MONTREAL, CANADA–(Marketwired – Aug 17, 2016) – Knight Therapeutics Inc. (TSX:GUD) (“Knight”), a leading Canadian specialty pharmaceutical company, today announced that Samira Sakhia, former CFO of Paladin Labs Inc. (“Paladin”), will be joining the Knight team as President and member of the Board of Directors. In her new role, beginning on August 31, 2016, Samira will report to Jonathan Ross Goodman, CEO of Knight.
“I am thrilled to once again be working alongside Samira as, even after 14 years together at Paladin, I continue to learn from her,” said Mr. Goodman. “I wouldn’t be stepping down as President unless I was convinced that Samira will do a GUD job and lead Knight towards fulfilling our mission of improving patients’ lives.”
“I am excited to join the Knight team and am grateful for this opportunity. I look forward to building Knight into Canada’s leading specialty pharmaceutical company,” said Ms. Sakhia.
About Samira Sakhia
Ms. Sakhia served as the CFO at Paladin (acquired by Endo International plc February 2014), a specialty pharmaceutical company from 2001 to 2015. At Paladin, Ms. Sakhia was responsible for the finance, operations, human resources and investor relations functions. During her employment with Paladin, Ms. Sakhia was instrumental in executing in-licensing and acquisition transactions of Canadian and international pharmaceutical products and businesses. In addition, Ms. Sakhia led several M&A and strategic lending transactions as well as equity rounds on the TSX and completed the sale of Paladin to Endo International for over $3 billion. Ms. Sakhia holds an MBA and a Bachelors of Commerce degree from McGill University and is also a Chartered Professional Accountant.
About Knight Therapeutics Inc.
Knight Therapeutics Inc., headquartered in Montreal, Canada, is a specialty pharmaceutical company focused on acquiring or in-licensing innovative pharmaceutical products for the Canadian and select international markets. Knight Therapeutics Inc.’s shares trade on TSX under the symbol GUD. For more information about Knight Therapeutics Inc., please visit the company’s web site at www.gud-knight.com or www.sedar.com.
This document contains forward-looking statements for Knight Therapeutics Inc. and its subsidiaries. These forward looking statements, by their nature, necessarily involve risks and uncertainties that could cause actual results to differ materially from those contemplated by the forward-looking statements. Knight Therapeutics Inc. considers the assumptions on which these forward-looking statements are based to be reasonable at the time they were prepared, but cautions the reader that these assumptions regarding future events, many of which are beyond the control of Knight Therapeutics Inc. and its subsidiaries, may ultimately prove to be incorrect. Factors and risks, which could cause actual results to differ materially from current expectations are discussed in Knight Therapeutics Inc.’s Annual Report and in Knight Therapeutics Inc.’s Annual Information Form for the year ended December 31, 2015. Knight Therapeutics Inc. disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information or future events, except as required by law.